Benzofuran derivatives as inhibitors of p38-α kinase

Details Benzofuran derivatives as inhibitors of p38-α kinase Benzofuran derivatives as inhibitors of p38-α kinase

2007-03-13

2007-03-13

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S254030, C514S254110, C514S320000, C544S370000, C544S373000, C544S376000, C544S377000, C546S196000

Reexamination Certificate

active

10146703

ABSTRACT:
The invention is directed to methods to inhibit p38-α kinase using compounds which contain an aromatic residue coupled to an benzofuran moiety through a piperidine.

REFERENCES:
patent: 3316260 (1967-04-01), Shen et al.
patent: 4088765 (1978-05-01), Winn et al.
patent: 4243806 (1981-01-01), Raeymaekers et al.
patent: 4454130 (1984-06-01), Tominaga et al.
patent: 4737501 (1988-04-01), Tominago et al.
patent: 4886809 (1989-12-01), Tamada et al.
patent: 5462934 (1995-10-01), Goto et al.
patent: 5696122 (1997-12-01), Gaster et al.
patent: 5698553 (1997-12-01), Prucher et al.
patent: 5714498 (1998-02-01), Kulagowski et al.
patent: 5726177 (1998-03-01), Halazy et al.
patent: 5795907 (1998-08-01), Kalindjian
patent: 6130235 (2000-10-01), Mavunkel
patent: 6410540 (2002-06-01), Goehring
patent: 6525042 (2003-02-01), Kobayashi et al.
patent: 0 318 235 (1989-05-01), None
patent: 318235 (1989-05-01), None
patent: 0 431 945 (1991-06-01), None
patent: 0 709 384 (1996-05-01), None
patent: 0 831 090 (1998-03-01), None
patent: 61-291566 (1986-12-01), None
patent: 2-184673 (1990-07-01), None
patent: 3-161-470 (1991-07-01), None
patent: 9-124631 (1997-09-01), None
patent: WO 96/40143 (1996-12-01), None
patent: WO 97/26252 (1997-07-01), None
patent: WO 98/06715 (1998-02-01), None
patent: WO 98/07425 (1998-02-01), None
patent: WO 98/28292 (1998-07-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/61426 (1999-12-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/59904 (2000-03-01), None
patent: WO-02/42292 (2002-05-01), None
patent: WO 02/44168 (2002-06-01), None
patent: WO-02/070491 (2002-06-01), None
CRC handbook p. 9-26-43 (2002).
Cecil textbook of Medicine, Saunders Co. p. 1395-1396.
Floyd et al. “Nitrone inhibition . . . ” CA 133:305179 (2000).
Adams et al. “Imidazole Compounds . . . ” CA 128:201066 (1998).
De Clerck et al. (1981).Throm. Res23: 1-12.
Dukic et al. (1997).Arch. Pharm330:25-28.
Eyers, P.A. et al. “Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution”,Chem and Biol(1995) 5:321-328.
Fischer, “Physical chemical properties and local anesthetic results of an ether substitute of procaine” CA 67:10051 (1996).
Gassman, P. G., “A General Method for the Synthesis of Indoles,” J. Am. Chem. Soc., (1974) 96(17):5495-5508.
Goehring et al. “Inhibitors of p-38-alpha . . . ” CA 132:203174 (2000).
International Search Report dated Jul. 29, 1999.
Jiang, Y. et al., “Characterization of the structure and function of a new mitogen-activated protein kinase (p38β)”J Biol Chem(1996) 271:17920-17926.
Kumar, S. et al. “Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyrinidyl imidazoles”,Biochem Biophys Res Comm(1997) 235:533-538.
Li, Z. et al. “The primary structure of p38γ: a new member of p38 group of MAP kinases”,Biochem Biophys Res Comm(1996) 228:334-340.
Mittendorf et al. “Preparation of Bis-Benzimidazoles . . . ” CA 132:265195 (2000).
Murai, Y., et al., “Synthesis of 4-, 5-, 6- and 7-Substituted N-Tosylindoles from Substituted Anilines,”Heterocycles, (1992) 34(5):1017-1029.
Nakai et al. (1994).CA121:222012.
Nakai et al. (1994).CA121:221997.
Oelschlaeger et al. (1988).CA109:73387.
Ogawa et al. “Studies on Positive Inotropic . . . ” CA 110:57613 (1988).
Otsuka Pharm. (1983).CA100:51465.
Otsuka Pharm. (1983).CA100:34414.
Otsuka Pharm. (1984).CA100:68187.
Patani et al. “Bioisosterism: A Rational Approach in Drug Design” Chem. Rev. 96:3147-3176 (1996).
Societe Des Usine Chemiques “Anticancerous 2-substituted . . . ” CA 77:34584 (1968).
Stein, B. et al. “p38-2, a novel mitogen-activated protein kinase with distinct properties”,J Biol Chem(1997) 272:19509-19517.
Tamada et al “Preparation of Benzoheterocycle . . . ” CA 111:153834 (1989).
Von Strandtmann. (1971).CA80:82713.
Wang, X.S., et al., “Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase”,J Biol Chem(1997) 272:23668-23674.
Wang, Y. et al. “Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family”,J Biol Chem(1998) 273:2161-2168.
Dinarello, Chest (2000) 118(2):503-508.
Fischer, CA (1996) 67:10051.
Hashimoto et al., Clinical and Experimental Allergy (1999-2000) 30:48-55.
Nick et al., J. Clin. Invest. (1997) 99:975-986.
Schmit et al., CA (1994) 122:53913.
Bennett (Ed.), Concise Chemical and Technical Dictionary, Chemical Publishing Co., Inc., New York (1974) pp.536-537.
Burger, “A guide to the chemical basis of drug design” Wiley Interscience, p.15 (1983).
Grant (Ed.), Hackh's Chemical Dictionary, McGraw-Hill Book Company (1983) pp. 320-321.
Trilateral project “comparative study on reach though claims” Nov. 2001, p.1.
Wilbraham et al., “Organic and biological chemistry” Southern Ill. Univ. p.387 (1984).

Affiliated with

Also associated with

Rating

Benzofuran derivatives as inhibitors of p38-α kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Benzofuran derivatives as inhibitors of p38-α kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzofuran derivatives as inhibitors of p38-α kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3765008